HIMS & HERS HEALTH INC (HIMS)

US4330001060 - Common Stock

19.42  -0.95 (-4.66%)

After market: 19.49 +0.07 (+0.36%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

HIMS & HERS HEALTH INC

NYSE:HIMS (5/31/2024, 7:04:00 PM)

After market: 19.49 +0.07 (+0.36%)

19.42

-0.95 (-4.66%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Providers & Services
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month119.93%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap4.17B
Shares
PEN/A
Fwd PE64.56
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

HIMS Daily chart

Company Profile

Hims & Hers Health, Inc. operates a telehealth consultation platform. The company is headquartered in San Francisco, California and currently employs 651 full-time employees. The company went IPO on 2019-09-09. The firm's digital platform enables access to treatments for a range of conditions, including those related to sexual health, hair loss, dermatology, mental health and primary care. The company connects patients to licensed healthcare professionals who can prescribe medications when appropriate. The prescriptions are fulfilled online through licensed pharmacies on a subscription basis. Through the Hims & Hers mobile applications, consumers can access a range of educational programs, wellness content, community support, and other services that promote lifelong health and wellness. The firm's products include shampoo, conditioner, biotin gummies, anti-aging cream, vitamin c serum, acne cream and moisturizer. Its products are sold in tens of thousands of retail locations in the United States.

Company Info

HIMS & HERS HEALTH INC

2269 Chestnut St, #523

San Francisco CALIFORNIA 94123

P: 14158510195

CEO: Andrew Dudum

Employees: 651

Website: https://www.forhims.com/

HIMS News

News Imagea day ago - The Motley FoolHims & Hers Health Stock Soared This Week: Here's Why

The company is still riding momentum from its recent weight loss drug announcement.

News Image5 days ago - Market News VideoNoteworthy Tuesday Option Activity: HIMS, CPRI, X
News Image5 days ago - The Motley FoolA New Name in Weight Loss Drugs

Novo Nordisk and Eli Lilly have soared on the popularity of GLP-1 weight loss drugs. Now Hims & Hers is trying to get in on the action with a more available and affordable option.

News Image5 days ago - The Motley FoolSoaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?

Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights.

News Image7 days ago - The Motley FoolThe Ultimate Growth Stock to Buy With $20 Right Now

I challenge you to name another $20 stock with more long-term potential.

News Image9 days ago - InvestorPlace7 Stocks to Dominate in the Next Economic Upturn

Discover the top stocks to buy for the next economic upturn, carefully selected for their robust growth potential.

HIMS Twits

Here you can normally see the latest stock twits on HIMS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example